Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) traded down 3% on Wednesday . The stock traded as low as $107.04 and last traded at $106.93. 1,893,791 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 6,677,408 shares. The stock had previously closed at $110.23.
Analyst Ratings Changes
Several brokerages recently issued reports on GILD. Oppenheimer lifted their price objective on Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a report on Tuesday, March 4th. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research report on Thursday, February 13th. BMO Capital Markets increased their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $104.52.
Get Our Latest Analysis on GILD
Gilead Sciences Stock Up 1.1 %
The firm has a market capitalization of $133.35 billion, a PE ratio of 289.41, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a 50-day moving average of $103.68 and a two-hundred day moving average of $93.96.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.95%. The ex-dividend date is Friday, March 14th. Gilead Sciences's payout ratio is currently 854.05%.
Insider Activity
In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 302,785 shares of company stock valued at $30,503,250. Company insiders own 0.29% of the company's stock.
Hedge Funds Weigh In On Gilead Sciences
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bellevue Group AG boosted its stake in shares of Gilead Sciences by 18.2% in the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company's stock valued at $3,859,000 after purchasing an additional 7,093 shares during the period. Quantinno Capital Management LP grew its stake in shares of Gilead Sciences by 149.5% during the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company's stock valued at $6,843,000 after acquiring an additional 48,910 shares in the last quarter. McAdam LLC increased its position in shares of Gilead Sciences by 16.7% during the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock worth $2,344,000 after acquiring an additional 3,627 shares during the last quarter. Capital Investment Advisors LLC lifted its stake in shares of Gilead Sciences by 2.6% in the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company's stock worth $35,793,000 after acquiring an additional 9,791 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in Gilead Sciences by 3.9% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company's stock valued at $13,132,000 after purchasing an additional 5,382 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
